Prasugrel-related hepatotoxicity

Authors

  • Zeki Dogan Department of Cardiology, Istanbul Atlas University, School of Medicine, Medicine Hospital, Turkey
  • Mustafa Yurtdas Department of Cardiology, Istanbul Atlas University, School of Medicine, Medicine Hospital, Turkey
  • Gokhan Bektasoglu Department of Cardiology, Istanbul Atlas University, School of Medicine, Medicine Hospital, Turkey

DOI:

https://doi.org/10.47391/JPMA.3179

Abstract

Prasugrel is usually preferred over Clopidogrel to reduce the risk of recurrent coronary thrombosis in patients who undergo percutaneous coronary interventions during an acute coronary syndrome owing to its more potent and more rapid antithrombotic activation. Little is known about Prasugrel-induced hepatotoxicity, although mild-to-moderate alanine transaminase (ALT) and gamma glutamyl transpeptidase (GGT) elevations have been noticed in post-marketing surveillance. Herein, we report the case of a patient with Prasugrel-related hepatotoxicity that was reverted after switching from Prasugrel to Ticagrelor.

Keywords: Percutanous coronary interventions, antiplatelet drug, Prasugrel, hepatotoxicity.

Downloads

Published

2022-10-15

How to Cite

Dogan, Z., Mustafa Yurtdas, & Gokhan Bektasoglu. (2022). Prasugrel-related hepatotoxicity. Journal of the Pakistan Medical Association, 72(11), 2295–2297. https://doi.org/10.47391/JPMA.3179

Issue

Vol. 72 No. 11 (2022): NOVEMBER

Section

CASE REPORT